Arax Advisory Partners’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $41.5M | Buy |
164,897
+116,040
| +238% | +$25M | 0.28% | 68 |
|
|
2026
Q1 | $10.6M | Sell |
48,857
-1,190
| -2% | -$264K | 0.3% | 73 |
|
|
2025
Q4 | $11.4M | Sell |
50,047
-4,199
| -8% | -$957K | 0.33% | 70 |
|
|
2025
Q3 | $12.6M | Buy |
54,246
+29,220
| +117% | +$5.95M | 0.18% | 79 |
|
|
2025
Q2 | $4.65M | Buy |
25,026
+12,863
| +106% | +$2.39M | 0.21% | 86 |
|
|
2025
Q1 | $2.55M | Buy |
12,163
+2,018
| +20% | +$392K | 0.16% | 97 |
|
|
2024
Q4 | $1.8M | Buy |
10,145
+2,675
| +36% | +$492K | 0.11% | 112 |
|
|
2024
Q3 | $1.48M | Buy |
7,470
+490
| +7% | +$91.5K | 0.13% | 88 |
|
|
2024
Q2 | $1.2M | Buy |
6,980
+1,172
| +20% | +$194K | 0.12% | 104 |
|
|
2024
Q1 | $1.06M | Sell |
5,808
-2,343
| -29% | -$404K | 0.11% | 103 |
|
|
2023
Q4 | $1.26M | Sell |
8,151
-395
| -5% | -$57.6K | 0.14% | 80 |
|
|
2023
Q3 | $1.27M | Buy |
8,546
+2,378
| +39% | +$349K | 0.16% | 73 |
|
|
2023
Q2 | $831K | Buy |
6,168
+121
| +2% | +$17.7K | 0.11% | 90 |
|
|
2023
Q1 | $964K | Buy |
6,047
+221
| +4% | +$33.8K | 0.13% | 78 |
|
|
2022
Q4 | $942K | Sell |
5,826
-377
| -6% | -$57.8K | 0.13% | 80 |
|
|
2022
Q3 | $832K | Buy |
6,203
+250
| +4% | +$35.9K | 0.13% | 75 |
|
|
2022
Q2 | $912K | Sell |
5,953
-360
| -6% | -$55K | 0.14% | 75 |
|
|
2022
Q1 | $1.02M | Buy |
6,313
+6
| +0.1% | +$872 | 0.14% | 76 |
|
|
2021
Q4 | $854K | Buy |
6,307
+134
| +2% | +$15.8K | 0.11% | 79 |
|
|
2021
Q3 | $666K | Buy |
6,173
+275
| +5% | +$31.4K | 0.09% | 87 |
|
|
2021
Q2 | $664K | Buy |
+5,898
| New | +$664K | 0.09% | 84 |
|
|
2020
Q4 | $489K | Buy |
4,565
+114
| +3% | +$11K | 0.07% | 90 |
|
|
2020
Q3 | $390K | Buy |
4,451
+73
| +2% | +$6.87K | 0.07% | 101 |
|
|
2020
Q2 | $430K | Sell |
4,378
-124
| -3% | -$10.9K | 0.08% | 88 |
|
|
2020
Q1 | $343K | Sell |
4,502
-58
| -1% | -$4.94K | 0.08% | 91 |
|
|
2019
Q4 | $404K | Buy |
4,560
+2,705
| +146% | +$225K | 0.12% | 79 |
|
|
2019
Q3 | $140K | Buy |
1,855
+2
| +0.1% | +$137 | 0.04% | 197 |
|
|
2019
Q2 | $135K | Buy |
+1,853
| New | +$146K | 0.04% | 188 |
|
|
2018
Q4 | $176K | Sell |
1,914
-64
| -3% | -$5.63K | 0.07% | 137 |
|
|
2018
Q3 | $187K | Buy |
+1,978
| New | +$188K | 0.08% | 125 |
|
Other funds holding ABBV
Arax Advisory Partners's ABBV Position: Q2 2026 in Review
Arax Advisory Partners increased its AbbVie (ABBV) stake by 238% in Q2 2026, buying an estimated $25M and bringing the position to 164,897 shares worth $41.5M. The position accounts for 0.28% of the portfolio, ranked #68.
Arax Advisory Partners first reported a position in ABBV in Q3 2018 and has held it in 30 quarters since. 4,192 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.
- Arax Advisory Partners held 164,897 shares of AbbVie worth $41.5M as of Q2 2026.
- Arax Advisory Partners bought 116,040 AbbVie shares in Q2 2026, an estimated $25M.
- AbbVie made up 0.28% of Arax Advisory Partners's portfolio in Q2 2026, its #68 holding.
- Arax Advisory Partners first reported a position in AbbVie in Q3 2018 and has held it in 30 quarters since.
- 4,192 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.
Based on Arax Advisory Partners's 13F filing for Q2 2026, filed 10 Aug 2026.